ELV vs HUM
Elevance Health and Humana, both Healthcare
Elevance Health is the larger company at $84B against $43B. On trailing earnings ELV is the cheaper of the two at a P/E of 17.8 against 41.7, a gap that is only a bargain if the two are growing at similar rates. Over the past year HUM returned +54% against +49% for ELV. Ryufin's sector-relative Smart Score puts ELV ahead, 7/10 against 6/10.
| Figure | ELV | HUM |
|---|---|---|
| Last close | $403 | $391 |
| Market cap | $84B | $43B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 17.8 | 41.7 |
| Dividend yield | n/a | 0.9% |
| 1-year return | +49% | +54% |
| 5-year return | +13% | -3.7% |
| Ryufin Smart Scoresector-relative, 1–10 | 7/10 | 6/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Elevance Health
Revenue of $50B in Q2 2026, net income $1.5B. Its largest reported line is Reportable, 89% of the disclosed total.
Humana
Revenue of $40B in Q1 2026, net income $1.2B. Its largest reported line is Center Well, 85% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.